Protect Your Bank Account with THESE 4 Simple Steps

Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.

Learn these 4 simple steps and protect your savings before it’s too late.

Maria Freire Biography and Net Worth

Director of Exelixis

Maria C. Freire, Ph.D., has been a director since April 2018. From November 2012 to September 2021, Dr. Freire served as President and Executive Director and as a member of the board of directors of the Foundation for the National Institutes of Health. Previously, she served as President and as a member of the board of directors of the Albert and Mary Lasker Foundation from 2008 to 2012, as President and Chief Executive Officer of the Global Alliance for TB Drug Development from 2001 to 2008 and as Director of the Office of Technology Transfer at the National Institutes of Health from 1995 to 2001.

Dr. Freire has served as a member of the board of directors of Biogen Inc., a publicly held biopharmaceutical company focused on the treatment of serious diseases, since June 2021, as a member of the board of directors of Alexandria Real Estate Equities, Inc., a publicly held urban office real estate investment trust uniquely focused on collaborative life science and technology campuses, since April 2012, and as a member of the board of directors of Koneksa Health, a privately held digital biomarker company, since July 2022. She has previously served on the boards of numerous national and international organizations, including the Science Board of the U.S. Food and Drug Administration, the World Health Organization Commission on Intellectual Property Rights, Innovation and Public Health and the United Nations Secretary General’s High Level Panel on Access to Medicines. Dr. Freire is also a member of the National Academy of Medicine and the Council on Foreign Relations, and she is the recipient of numerous awards, including a 2017 Gold Stevie Award for “Woman of the Year,” the U.S. Department of Health and Human Services Secretary’s Award for Distinguished Service, the Arthur S. Fleming Award and the Bayh-Dole Award. Dr. Freire holds a Ph.D. in Biophysics from the University of Virginia and a B.S. from the Universidad Peruana Cayetano Heredia in Lima, Peru.

What is Maria C. Freire's net worth?: The estimated net worth of Maria C. Freire is at least $2.41 million as of August 14th, 2024. Dr. Freire owns 91,007 shares of Exelixis stock worth more than $2,408,045 as of September 16th. This net worth evaluation does not reflect any other investments that Dr. Freire may own. Learn More about Maria C. Freire's net worth.
How do I contact Maria C. Freire?: The corporate mailing address for Dr. Freire and other Exelixis executives is 1851 Harbor Bay Parkway, Alameda CA, 94502. Exelixis can also be reached via phone at (650) 837-7000 and via email at [email protected]. Learn More on Maria C. Freire's contact information.
Has Maria C. Freire been buying or selling shares of Exelixis?: In the last ninety days, Maria C. Freire has sold $219,120.00 in Exelixis stock. Most recently, Maria C. Freire sold 8,250 shares of the business's stock in a transaction on Wednesday, August 14th. The shares were sold at an average price of $26.56, for a transaction totalling $219,120.00. Following the completion of the sale, the director now directly owns 91,007 shares of the company's stock, valued at $2,417,145.92. Learn More on Maria C. Freire's trading history.
Who are Exelixis' active insiders?: Exelixis' insider roster includes Dana Aftab (EVP), Charles Cohen (Director), Carl Feldbaum (Director), Maria Freire (Director), Maria Freire (Director), Alan Garber (Director), Patrick Haley (EVP), Jeffrey Hessekiel (EVP), David Johnson (Director), Peter Lamb (EVP), Vincent Marchesi (Director), Michael Morrissey (CEO), Stelios Papadopoulos (Director), George Poste (Director), Gisela Schwab (CMO), Christopher Senner (CFO), Lance Willsey (Director), and Jack Wyszomierski (Director). Learn More on Exelixis' active insiders.
Are insiders buying or selling shares of Exelixis?: In the last year, Exelixis insiders bought shares 4 times. They purchased a total of 735,409 shares worth more than $15,270,038.49. In the last year, insiders at the biotechnology company sold shares 15 times. They sold a total of 514,128 shares worth more than $12,698,599.85. The most recent insider tranaction occured on August, 26th when EVP Jeffrey Hessekiel sold 20,000 shares worth more than $515,800.00. Insiders at Exelixis own 2.9% of the company. Learn More about insider trades at Exelixis.
Information on this page was last updated on 8/26/2024.

Maria C. Freire Insider Trading History at Exelixis

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/14/2024	Sell	8,250	$26.56	$219,120.00	91,007

Maria C. Freire Buying and Selling Activity at Exelixis

Exelixis Company Overview

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Today's Range

Now: $27.47

$26.55

$27.49

50 Day Range

MA: $24.72

$22.05

$27.17

2 Week Range

Now: $27.47

$18.64

$27.53

Volume

1,197,079 shs

Average Volume

2,020,888 shs

Market Capitalization

$8.33 billion

P/E Ratio

42.92

Dividend Yield

N/A

Beta

0.54

Introducing the Perceptron

From Brownstone Research | Ad

On Wednesday, September 25, I’m putting on my first crypto event in two years to unveil: the Perceptron. This is my AI project that I first conceived of shortly after I recommended Nvidia back in 2016.

Just click here to register.